Aditya Kohli, a director at HilleVax, Inc. (NASDAQ:HLVX), a biopharmaceutical company, recently sold a total of 18,000 shares of the company's common stock, resulting in proceeds exceeding $266,000. The transactions took place over a span of three days, with the sale prices ranging between $14.205 and $15.4482 per share.
On May 20, 2024, Kohli sold 6,000 shares at a weighted average price of $15.4482, with individual sale prices varying from $15.13 to $15.82. The following day, another 6,000 shares were sold at an average price of $14.205, with sales executed in a range from $14.00 to $14.41. The final batch of 6,000 shares was sold on May 22 at an average price of $14.7287.
The sales were conducted in accordance with a Rule 10b5-1 trading plan, which Kohli had adopted on October 12, 2023. This plan allows company insiders to set up a predetermined schedule for buying or selling securities to avoid accusations of trading on inside information.
Following the series of transactions, Kohli's ownership in HilleVax has been adjusted to 764,878 shares. Investors often monitor insider sales as they may offer insights into the executive's view of the company's current valuation and future prospects.
HilleVax, Inc. specializes in the development of biological products, with a focus on advancing innovative treatments for infectious diseases. The company is incorporated in Delaware and headquartered in Boston, MA.
InvestingPro Insights
Amidst the recent insider sales at HilleVax, Inc. (NASDAQ:HLVX), investors are keenly observing the company's financial health and market performance. According to InvestingPro data, HilleVax currently holds a market capitalization of approximately $689.82 million. Despite challenges, the company's liquid assets are reported to exceed its short-term obligations, indicating a degree of financial stability in the near term.
Analyzing the company's performance metrics, HilleVax's price per share stands at $14.53, which is 69.93% of its 52-week high, reflecting a potential room for growth according to market trends. Furthermore, with a negative Return on Assets of -46.66% over the last twelve months as of Q1 2024, it underscores the company's current challenges in generating profits from its assets.
InvestingPro Tips suggest that while HilleVax holds more cash than debt, it is quickly burning through cash and suffers from weak gross profit margins. Interestingly, 4 analysts have revised their earnings upwards for the upcoming period, providing a glimmer of hope for future financial performance. However, analysts do not expect the company to be profitable this year, and HilleVax does not pay a dividend, which might be a consideration for income-focused investors.
For those looking to delve deeper into HilleVax's financials and future outlook, InvestingPro offers additional insights and tips. There are currently 7 more InvestingPro Tips available for HilleVax, which can be accessed to help investors make more informed decisions. To explore these insights, investors can use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.